| abstract |
A method of treating a host of neuromuscular, neurodegenerative, developmental, nautoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, nstroke, Huntington's disease, Epilepsy, Multiple Sclerosis (MS), Lupus, Type-i and nType-2 diabetes, Maturity Onset Diabetes of the Young (MODY), myasthenia gravis n(MG), rheumatoid arthritis (RA), Graves' disease, Guillain-Barr6 syndrome (GBS), nmetabolic syndrome, Muscular Dystrophy or Duchenne Muscular Dystrophy (DMD), nsevere bums, aging, Amyotrophic Lateral Sclerosis (ALS), Friedreich's Ataxia, Batten nDisease, Alzheimer's disease, optic neuritis, Leber's hereditary optic neuropathy n(LHON), autism, Rett syndrome, Batten Disease, Angelman's Syndrome, Leigh disease, nFragile-X Syndrome, depression, Parkinson's disease, mitochondrial diseases, ndevelopmental disorders, metabolic disease disorders and/or autoimmune ndisorders by inducing endogenous BDNF expression with DNP treatment to protect nfrom neuromuscular dysfunction/disorders and/or neurodegeneration and/or muscle nwasting. DNP was administered to mice daily over a range of doses, and subsequently nBDNF expression in the brain showed a dose dependent and non-linear increase in nexpression. n68 |